


## REMARKS

Applicants respectfully request that the foregoing amendments to Claims 3 through 9 be entered in order to avoid this application incurring a surcharge for the presence of one or more multiple dependent claims. A marked-up version of the claims showing the changes made is attached.

Respectfully submitted,

December 7, 2001

Date

  
\_\_\_\_\_  
Richard L. Schwaab  
Registration No. 25,479

FOLEY & LARDNER  
3000 K Street, N.W. Suite 500  
Washington, D.C. 20007-5109  
(202) 672-5300

**VERSIONS WITH MARKINGS TO SHOW CHANGES MADE**

3. Use according to claim 1[ or 2], characterised in that the R-enantiomers are used in pure form or, in comparison with the racemate, in enriched form.
4. Use according to claim 1[ to 3], characterised in that the glucuronidase inhibitor is used, with suitable pharmacologically compatible adjuvants, orally or parenterally in normally liberating or controlled liberating form.
5. Use according to claim 1[ to 4], characterised in that the glucuronidase inhibitor is used alone for the inhibition of  $\beta$ -glucuronidase in diseased tissue in order to prevent the progress of the disease, e.g. by inhibition of the tumour progression or the metastasis formation.
6. Use according to claim 1[ to 4], characterised in that the glucuronidase inhibitor is used for the stabilisation of metabolically-formed glucuronide conjugates of side-effect-rich active materials in order to reduce their side effects or to introduce a detoxification.
7. Use according to claim 1[ to 4], characterised in that the glucuronidase inhibitor is used combined with a glucuronide conjugate of an inflammation-inhibiting active material to be taken orally in order to protect this in the upper stomach-intestine tract against a cleavage and resorption and to activate in the deeper lying intestinal sections by cleavage for the intestinal local therapy.
8. Use according to claim 1[ to 4] for the improvement of the tissue-specific therapy, characterised in that the glucuronidase inhibitor, in the case of combined use with a glucuronide prodrug, protects this against activation in healthy tissue in the case of maintenance of the activation in the target tissue.
9. Use according to claim 1[ to 4 and 8], characterised in that, besides the glucuronidase inhibitor and the glucuronide prodrug, there is used combined beta-

glucuronidase bound to tissue-specific substances (e.g. antibodies, proteins, liposomes) in order to increase the activation of the prodrug in the target tissue and to protect the healthy tissue against the activation